JUBILANT PHARMOVA LIMITED (JUBLPHARMA): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹966 latest close · −0.3% over the last 90 sessions

₹966 month-end · −11.4% over 12 months

₹966 month-end · +124.9% over 3 years

₹966 month-end · +37.3% since Jan '19

52-week range ₹786.05 to ₹1183.00 · 1-year volatility 28.7%

Was the rally earned?

1 year5 years

-11%share price, 1 yearEarnings-driven

Mostly earnings.

Per-share earnings took off 25 points, while the multiple moved less (P/E 37.7x to 43.7x).
The share count barely moved.

Net profit growth-24 ptsNet profit fell about 23%, which lowers the price.

P/E change+14 ptsThe P/E rose from 37.7x to 43.7x, which lifts the price.

Share count change-1 ptsShare count was little changed. More shares would count against the price.

+66%share price, 5 yearsMultiple-driven

Partly.

Most of the rise came from investors paying a higher multiple (P/E 11.1x to 43.7x); per-share earnings took off 112 points.
The share count barely moved.

Net profit growth-112 ptsNet profit fell about 58%, which lowers the price.

P/E change+178 ptsThe P/E rose from 11.1x to 43.7x, which lifts the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-73.5%recovered 2024-09

1-year volatility28.7%annualised

Beta vs sector index0.983-year daily, correlation 0.37

Volume spikes8last 90 sessions, 5x the 50-day median

Drawdown from peak

Largest drawdowns

-73.5% (2021-02 peak to 2023-03 low, recovered 2024-09)

-73.2% (2019-03 peak to 2020-03 low, recovered 2020-08)

-36.0% (2024-11 peak to 2026-03 low, not yet recovered)

Most recent volume spikes

2026-10-12: 7.2x the 50-day median, price +2.0% that day

2026-09-29: 6.1x the 50-day median, price -1.2% that day

2026-09-08: 10.8x the 50-day median, price +5.0% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

43.7xP/E todayNear its historic high

Against its own history95th percentile

CheapestMedian 14.4xDearest

Usual range 11.1x to 37.7x since 2019-01.

Against Health Technology43.7x vs 37.0x

This company

43.7x

Sector median

37.0x

18% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE31stflat vs a year ago
Op. margin34th▼ 8 pts vs a year ago
Revenue growth62nd▲ 11 pts vs a year ago
EPS growth23rd▼ 3 pts vs a year ago
Debt/equity ↓21st▼ 8 pts vs a year ago
Cash cycle ↓89th▲ 9 pts vs a year ago
P/E ↓38th▼ 3 pts vs a year ago
12M momentum25th▼ 32 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~24%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 46.3x, a holder earning 12%/yr needs earnings to grow about 24.4%/yr for 10 years, then trade at 15x.

Delivered−4.4%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg

Gap+28.7 ptsimplied minus delivered

Rank63rdmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

Change the assumptions

Exit P/E / return	11%	12%	13%
12x	25.9%	27.0%	28.2%
15x	23.3%	24.4%	25.5%
20x	19.9%	21.0%	22.1%

Drag a slider to test other assumptions

Required return 12.0% Years 10 Exit P/E 15x Implied: 24.4%/yr

Looking back

Jan 2020Price implied 16%/yr; EPS has since grown −5%/yr (7.0 yrs)
Jan 2021Price implied 16%/yr; EPS has since grown −13%/yr (6.0 yrs)
Jan 2022Price implied 9%/yr; EPS has since grown −14%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹966.00
P/E: 43.7x
ROCE: 9.0%
Market Cap: ₹15385 cr
Revenue (TTM): ₹8607 cr
P/S: 1.8x
P/B: 2.2x
ROE: 5.0%
Operating Margin: 11.0%
Debt / Equity: 0.5x
Promoter Holding: 47.7%
12M Momentum: -11.3%

52-week range

₹786.05₹1183.00

45% of the way from its 52-week low to its high

Price risk

1Y volatility

28.7%

Beta vs sector

1-year daily

0.81

Balance sheet & cash

Interest cover

operating profit ÷ interest

3.5x

Cash from profit, 3Y

operating cash flow ÷ net profit

2.50x

Share count, 1Y

unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold

Other income reliance3%Within range

Other income as a share of pre-tax profit (trailing twelve months): 2.8%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate31%Within range

Median quarterly effective tax rate over about 2.5 years: 30.5%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion2.50xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 2.50x (cash from operations ₹3,270 cr, net profit ₹1,307 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history-3 daysWithin range

Debtor days are below the median of the previous three fiscal years by 3 days (47 vs 50). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress58% of fixed assetsWithin range

Capital work-in-progress is 58% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+24 days / 2 yrsWithin range

Days payable changed by +24 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, DIIs added 10.8 pts; FIIs trimmed 7.3 pts; promoters trimmed 3.0 pts.
The number of shareholders fell from 89,376 to 82,703 (-7%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters50.7%47.7%-3.0 pts

FIIs23.2%15.9%-7.3 pts

DIIs1.6%12.4%+10.8 pts

Public and others23.9%23.5%-0.4 pts

Number of shareholders

82,703shareholders-7% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−4.8%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like JUBILANT PHARMOVA LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −20% to +15% vs the market, against −7% for all non-financial companies in the same months.
The gap against the base rate (+2.0%, 80% range −5.9% to +8.7%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median

−4.8%

All companies' median

−6.8%

Beat the market

44% vs 43%

50 past situations · 50 companies · 29 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
JKCEMENT Non-Energy Minerals	Sep 2023	58x	10%	+21%	−7%	+1%
SUPRAJIT Producer Manufacturing	Oct 2025	56x	11%	−13%	−16%	+12%
RAMCOCEM Non-Energy Minerals	Jan 2024	77x	6%	+51%	−3%	−17%
TRIDENT Process Industries	May 2025	55x	10%	−13%	−22%	−25%
BANARISUG Process Industries	May 2023	43x	7%	+11%	−12%	−40%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
GODREJIND Process Industries	Sep 2020	25x	10%	+1%	−12%	−14%
SFL Process Industries	Feb 2025	48x	8%	−31%	−32%	−35%
CENTURYPLY Producer Manufacturing	Oct 2025	83x	10%	−11%	−13%	−11%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to JUBILANT PHARMOVA LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

THE RAMCO CEMENTSRAMCOCEM

Non-Energy Minerals

71%similar

revenuedebt/equity

MEDPLUS HEALTH SERVICESMEDPLUS

Retail Trade

68%similar

volatilityrevenue

AFCONS INFRASTRUCTUREAFCONS

Industrial Services

67%similar

revenuepromoter holding

SUPRAJIT ENGINEERINGSUPRAJIT

Producer Manufacturing

66%similar

promoter holdingoperating margin

BHARAT FORGEBHARATFORG

Producer Manufacturing

63%similar

revenue growthvolatility

DR REDDYS LABORATORIESDRREDDY

Health Technology

60%similar

operating marginrevenue growth

PIRAMAL PHARMAPPLPHARMA

Health Technology

59%similar

revenuerevenue growth

BIOCONBIOCON

Health Technology

55%similar

debt/equitypromoter holding

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Feb '24

2026
OctPriceVolume reached 7.2x its 50-day median on 2026-10-12; price +2.0% that day.
SepValuationP/E crossed above the 90th percentile of its own history to date (46.5x).
AugPriceVolume reached 18.0x its 50-day median on 2026-08-24; price +2.5% that day.
MayValuationP/E crossed above the 90th percentile of its own history to date (36.6x).
AprPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
MarPriceFell 36% from the Nov 2024 peak to the Mar 2026 low.
FebPriceVolume reached 6.2x its 50-day median on 2026-02-09; price +0.5% that day.
2025
NovPriceVolume reached 6.5x its 50-day median on 2025-11-03; price +6.2% that day.

Show 22 earlier events

2025
SepPromoterPromoter holding fell 3.0 pts to 47.7%.
SepResultsYear-on-year EPS growth turned negative.
SepValuationP/E crossed above the 90th percentile of its own history to date (37.4x).
SepPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
JulPriceVolume reached 6.8x its 50-day median on 2025-07-30; price +7.2% that day.
JunResultsYear-on-year EPS growth turned positive.
JunPeer rankMoved into the 3rd quartile of Health Technology on ROCE (from the bottom quartile).
JunDividendDividend payout cut from 102% to 9% of profit.
JunPriceVolume reached 28.9x its 50-day median on 2025-06-13; price -2.8% that day.
MayValuationP/E crossed above the 90th percentile of its own history to date (29.8x).
MarPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
FebPriceVolume reached 11.4x its 50-day median on 2025-02-05; price +10.3% that day.
2024
DecPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
DecPriceVolume reached 5.0x its 50-day median on 2024-12-16; price -2.9% that day.
SepPriceRegained the 2021-02 peak, 18 months after the low.
SepPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
AugPriceVolume reached 68.8x its 50-day median on 2024-08-01; price +12.0% that day.
JunResultsEPS (TTM) turned positive.
JunValuationP/E crossed above the 90th percentile of its own history to date (153.2x).
JunDividendStarted paying a dividend (payout 102% of profit).
AprPriceVolume reached 15.0x its 50-day median on 2024-04-04; price +9.9% that day.
FebPriceVolume reached 10.3x its 50-day median on 2024-02-02; price +2.7% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	43.7x	₹8607 cr	5.0%	9.0%	0.5x
2026-10	41.8x	₹8607 cr	4.9%	9.0%	0.5x
2026-09	46.5x	₹8607 cr	4.9%	9.0%	0.5x
2026-08	35.2x	₹8279 cr	5.6%	9.0%	0.5x
2026-07	37.4x	₹8279 cr	5.6%	9.0%	0.5x
2026-06	38.8x	₹8279 cr	5.6%	9.0%	0.5x
2026-05	36.6x	₹7918 cr	6.9%	10.0%	0.4x
2026-04	34.1x	₹7918 cr	6.9%	10.0%	0.4x
2026-03	30.1x	₹7918 cr	6.9%	10.0%	0.4x
2026-02	28.9x	₹7618 cr	7.6%	10.0%	0.4x
2026-01	32.8x	₹7618 cr	7.6%	10.0%	0.4x
2025-12	35.8x	₹7618 cr	7.6%	10.0%	0.4x
2025-11	37.7x	₹7404 cr	7.3%	10.0%	0.4x
2025-10	38.1x	₹7404 cr	7.3%	10.0%	0.4x
2025-09	37.4x	₹7404 cr	7.3%	10.0%	0.4x
2025-08	19.4x	₹7235 cr	13.4%	10.0%	0.4x
2025-07	22.7x	₹7235 cr	13.4%	10.0%	0.4x
2025-06	23.0x	₹7235 cr	13.4%	10.0%	0.4x
2025-05	29.8x	₹7065 cr	11.5%	7.0%	0.7x
2025-04	22.8x	₹7065 cr	11.5%	7.0%	0.7x
2025-03	22.8x	₹7065 cr	11.5%	7.0%	0.7x
2025-02	24.3x	₹6920 cr	10.8%	7.0%	0.7x
2025-01	26.2x	₹6920 cr	10.8%	7.0%	0.7x
2024-12	29.7x	₹6920 cr	10.8%	7.0%	0.7x
2024-11	35.6x	₹6848 cr	10.1%	7.0%	0.7x
2024-10	34.9x	₹6848 cr	10.1%	7.0%	0.7x
2024-09	33.2x	₹6848 cr	10.1%	7.0%	0.7x
2024-08	190.4x	₹6703 cr	1.3%	7.0%	0.7x
2024-07	160.1x	₹6703 cr	1.3%	7.0%	0.7x
2024-06	153.2x	₹6703 cr	1.3%	7.0%	0.7x
2024-05	—	₹6282 cr	-1.2%	3.0%	0.7x
2024-04	—	₹6282 cr	-1.2%	3.0%	0.7x
2024-03	—	₹6282 cr	-1.2%	3.0%	0.7x
2024-02	—	₹6282 cr	-1.2%	3.0%	0.7x
2024-01	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-12	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-11	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-10	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-09	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-08	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-07	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-06	—	₹6282 cr	-1.2%	3.0%	0.7x
2023-05	12.7x	₹6130 cr	7.8%	10.0%	0.6x
2023-04	12.0x	₹6130 cr	7.8%	10.0%	0.6x
2023-03	10.7x	₹6130 cr	7.8%	10.0%	0.6x
2023-02	11.8x	₹6130 cr	7.8%	10.0%	0.6x
2023-01	13.5x	₹6130 cr	7.8%	10.0%	0.6x
2022-12	14.4x	₹6130 cr	7.8%	10.0%	0.6x
2022-11	15.1x	₹6130 cr	7.8%	10.0%	0.6x
2022-10	14.1x	₹6130 cr	7.8%	10.0%	0.6x
2022-09	12.9x	₹6130 cr	7.8%	10.0%	0.6x
2022-08	13.5x	₹6130 cr	7.8%	10.0%	0.6x
2022-07	13.9x	₹6130 cr	7.8%	10.0%	0.6x
2022-06	13.2x	₹6130 cr	7.8%	10.0%	0.6x
2022-05	7.3x	₹6099 cr	17.6%	12.0%	0.6x
2022-04	9.0x	₹6099 cr	17.6%	12.0%	0.6x
2022-03	7.4x	₹6099 cr	17.6%	12.0%	0.6x
2022-02	7.6x	₹6099 cr	17.6%	12.0%	0.6x
2022-01	9.9x	₹6099 cr	17.6%	12.0%	0.6x
2021-12	11.2x	₹6099 cr	17.6%	12.0%	0.6x
2021-11	11.1x	₹6099 cr	17.6%	12.0%	0.6x
2021-10	11.4x	₹6099 cr	17.6%	12.0%	0.6x
2021-09	11.9x	₹6099 cr	17.6%	12.0%	0.6x
2021-08	12.6x	₹6099 cr	17.6%	12.0%	0.6x
2021-07	13.1x	₹6099 cr	17.6%	12.0%	0.6x
2021-06	14.0x	₹6099 cr	17.6%	12.0%	0.6x
2021-05	15.5x	₹5976 cr	16.0%	15.0%	0.9x
2021-04	14.2x	₹5976 cr	16.0%	15.0%	0.9x
2021-03	12.1x	₹5976 cr	16.0%	15.0%	0.9x
2021-02	13.6x	₹5976 cr	16.0%	15.0%	0.9x
2021-01	15.8x	₹5976 cr	16.0%	15.0%	0.9x
2020-12	15.0x	₹5976 cr	16.0%	15.0%	0.9x
2020-11	12.8x	₹5976 cr	16.0%	15.0%	0.9x
2020-10	12.9x	₹5976 cr	16.0%	15.0%	0.9x
2020-09	13.0x	₹5976 cr	16.0%	15.0%	0.9x
2020-08	13.9x	₹5976 cr	16.0%	15.0%	0.9x
2020-07	14.1x	₹5976 cr	16.0%	15.0%	0.9x
2020-06	11.6x	₹5976 cr	16.0%	15.0%	0.9x
2020-05	12.3x	₹9111 cr	12.0%	16.0%	1.0x
2020-04	11.1x	₹9111 cr	12.0%	16.0%	1.0x
2020-03	6.9x	₹9111 cr	12.0%	16.0%	1.0x
2020-02	14.0x	₹9111 cr	12.0%	16.0%	1.0x
2020-01	16.2x	₹9111 cr	12.0%	16.0%	1.0x
2019-12	14.9x	₹9111 cr	12.0%	16.0%	1.0x
2019-11	14.1x	₹9111 cr	12.0%	16.0%	1.0x
2019-10	15.3x	₹9111 cr	12.0%	16.0%	1.0x
2019-09	14.0x	₹9111 cr	12.0%	16.0%	1.0x
2019-08	12.2x	₹9111 cr	12.0%	16.0%	1.0x
2019-07	12.2x	₹9111 cr	12.0%	16.0%	1.0x
2019-06	14.2x	₹9111 cr	12.0%	16.0%	1.0x
2019-05	12.3x	₹7518 cr	15.5%	15.0%	0.8x
2019-04	16.4x	₹7518 cr	15.5%	15.0%	0.8x
2019-03	16.5x	₹7518 cr	15.5%	15.0%	0.8x
2019-02	19.4x	₹7518 cr	15.5%	15.0%	0.8x
2019-01	17.4x	₹7518 cr	15.5%	15.0%	0.8x

Methodology and data notes